CAMBRIDGE, Mass., Jan. 8, 2014 /PRNewswire/ -- Catabasis Pharmaceuticals Inc. today announced that Jill Milne, Ph.D., Catabasis' co-founder and chief executive officer, will present an update on Catabasis at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Dr. Milne's presentation is scheduled for 9:30 a.m. PST on Thursday, January 16, 2014 in the Elizabethan C/D Ballroom of the Westin St. Francis Hotel.
Catabasis is a clinical-stage company dedicated to the discovery and development of innovative medicines to treat inflammatory and metabolic diseases. The company's drug development programs are rooted in the principles of pathway pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its proprietary SMART Linker technology, the company conjugates two drugs that act on different components of a disease pathway with the goal of producing new chemical entities with significantly enhanced efficacy and improved safety and tolerability profiles. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. The company was founded in 2008 and is headquartered in Cambridge, Mass.
Please visit www.catabasis.com for more information.
SOURCE Catabasis Pharmaceuticals Inc.